Stanford Medicine‘s history in cancer immunotherapy dates back to the 1980s – from researching personalized anticancer antibodies to treating pediatric leukemia with T-cells. More recently, Stanford scientists created a host of tools essential to new immunotherapy treatments. They shed light on T-cells, giving scientists a fresh look at the immune system through single-cell analysis and enable the mapping of regulatory DNA. This technology is being used across our research platform, driving PICI research forward. Crystal Mackall, MD | Director Mark Davis, PhD | Co-Director All Investigators Related Research Update Where Cancer-killing T-cells Come From Announcement PICI Young Investigator Retreat 2019 Research Update Predicting Childhood Leukemia Relapse Using Machine Learning Point of View PICI Catalyzes Scientific Innovation Cancer Research Heroes An Insider View of PICI’s Pancreatic Clinical Trial PRINCE Cancer Research Heroes PICI Takes On Prostate Cancer: A Q&A with the Experts Research Project TRIBUTE Cancer Research Heroes A Visionary Paving the Way for Faster and Better Cancer Cures Announcement Note from PICI’s President and CEO Jeff Bluestone: Introducing Our New Brand